Puma Biotech (PBYI) Tops Q2 EPS by 9c

Puma Biotech (NASDAQ: PBYI) reported Q2 EPS of ($1.17), $0.09 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $50.8 million versus the consensus estimate of $45.67 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• zSpace, Inc. (ZSPC) Reports Q2 results
• Lument Finance Trust (LFT) Misses Q2 EPS by 17c